Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospira The Holdout

Executive Summary

The Generic Pharmaceutical Association's reunification is not entirely complete. Hospira, alone among large firms that had left the association, has opted to remain a former member.

You may also be interested in...



"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.

"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.

GPhA Enters 2011 Bigger And Stronger, But With A Broader Fight On Its Hands

The Generic Pharmaceutical Association is pretty fond of Florida. The group has held its annual meeting in the state almost every year since the association was formed. But regardless of the weather or the hotel amenities, when GPhA convenes in Orlando next month, its members will be slightly disappointed in the venue: Florida is below the national average in the generic utilization rate for its Medicaid program.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel